CoChat

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Open access
Pérez-Guijarro, Eva, Yang, Howard H., Araya, Romina E., El Meskini, Rajaa, Michael, Helen T., Vodnala, Suman Kumar, Marie, Kerrie L., Smith, Cari, Chin, Sung, Lam, Khiem C., Thorkelsson, Andres, Iacovelli, Anthony J., Kulaga, Alan, Fon, Anyen, Michalowski, Aleksandra M., Hugo, Willy, Lo, Roger S., Restifo, Nicholas P., Sharan, Shyam K., Van Dyke, Terry, Goldszmid, Romina S., Weaver Ohler, Zoe, Lee, Maxwell P., Day, Chi-Ping, Merlino, Glenn · 2020 · Nature Medicine
Cited by 118

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Although immunotherapy has revolutionized cancer treatment, only a subset of patients demonstrate durable clinical benefit. Definitive predictive biomarkers and targets to overcome resistance remain unidentified, underscoring the urgency to develop reliable immunocompetent models for mechanistic assessment. Here we characterize a panel of syngeneic mouse models, representing a variety of molecular and phenotypic subtypes of human melanomas and exhibiting their diverse range of responses to immune checkpoint blockade (ICB). Comparative analysis of genomic, transcriptomic and tumor-infiltrating immune cell profiles demonstrated alignment with clinical observations and validated the correlation of T cell dysfunction and exclusion programs with resistance. Notably, genome-wide expression analysis uncovered a melanocytic plasticity signature predictive of patient outcome in response to ICB, suggesting that the multipotency and differentiation status of melanoma can determine ICB benefit. Our comparative preclinical platform recapitulates melanoma clinical behavior and can be employed to identify mechanisms and treatment strategies to improve patient care. Genetically engineered mouse models representing the spectrum of human cutaneous melanoma provide a platform for studying clinical responses to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0818-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 41

  1. Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581–598 (2018). · DOI · Paper page
  2. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014). · DOI · Paper page
  3. Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84–91 (2017). · DOI · Paper page
  4. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015). · DOI · Paper page
  5. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014). · DOI · Paper page
  6. Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018). · DOI · Paper page
  7. Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018). · DOI · Paper page
  8. Chin, L. et al. Cooperative effects of INK4a and Ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822–2834 (1997). · DOI · Paper page
  9. Ackermann, J. et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005–4011 (2005). · DOI · Paper page
  10. Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 15, 294–303 (2009). · DOI · Paper page
  11. Damsky, W. E. et al. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741–754 (2011). · DOI · Paper page
  12. Veierod, M. B., Adami, H. O., Lund, E., Armstrong, B. K. & Weiderpass, E. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics and nevi. Cancer Epidemiol. Biomarkers Prev. 19, 111–120 (2010). · DOI · Paper page
  13. Day, C. P., Marchalik, R., Merlino, G. & Michael, H. Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance. Lab. Invest. 97, 698–705 (2017). · DOI
  14. Noonan, F. P. et al. Neonatal sunburn and melanoma in mice. Nature 413, 271–272 (2001). · DOI · Paper page
  15. Day, C. P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39–53 (2015). · DOI · Paper page
  16. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013). · DOI · Paper page
  17. Vidwans, S. J. et al. A melanoma molecular disease model. PloS ONE. 6, e18257 (2011). · DOI
  18. Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017). · DOI · Paper page
  19. Chen, L. et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523–532 (1994). · DOI · Paper page
  20. Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–459 (1997). · DOI · Paper page
  21. Wolkers, M. C., Brouwenstijn, N., Bakker, A. H., Toebes, M. & Schumacher, T. N. Antigen bias in T cell cross-priming. Science 304, 1314–1317 (2004). · DOI · Paper page
  22. Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P. & Rossjohn, J. Unconventional T cell targets for cancer immunotherapy. Immunity 48, 453–473 (2018). · DOI · Paper page
  23. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015). · DOI · Paper page
  24. Chen, Z. et al. Inference of immune cell composition on the expression profiles of mouse tissue. Sci. Rep. 7, 40508 (2017). · DOI · Paper page
  25. Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell 177, 556–571 (2019). · DOI · Paper page
  26. Vandamme, N. & Berx, G. From neural crest cells to melanocytes: cellular plasticity during development and beyond. Cell Mol. Life Sci. 76, 1919–1934 (2019). · DOI
  27. Marie, K. L. et al. Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis. Nat. Commun. 11, 333 (2020). · DOI
  28. Joshi, S. S. et al. CD34 defines melanocyte stem cell subpopulations with distinct regenerative properties. PLoS Genet. 15, e1008034 (2019). · DOI
  29. Landsberg, J. et al. Melanomas resist T cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412–416 (2012). · DOI · Paper page
  30. Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 8, 935–943 (2018). · DOI · Paper page
  31. Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674–687 (2014). · DOI · Paper page
  32. Vasioukhin, V., Degenstein, L., Wise, B. & Fuchs, E. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc. Natl Acad. Sci. USA 96, 8551–8556 (1999). · DOI · Paper page
  33. Virador, V. et al. Production of melanocyte-specific antibodies to human melanosomal proteins: expression patterns in normal human skin and in cutaneous pigmented lesions. Pigment Cell Res. 14, 289–297 (2001). · DOI · Paper page
  34. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013). · DOI · Paper page
  35. Araya, R. E. & Goldszmid, R. S. Characterization of the tumor immune infiltrate by multiparametric flow cytometry and unbiased high-dimensional data analysis. Methods Enzymol. 632, 309–337 (2020). · DOI
  36. Chen, H. et al. Cytofkit: A bioconductor package for an integrated mass cytometry data analysis pipeline. PLoS Comput. Biol. 12, e1005112 (2016). · DOI · Paper page
  37. Schrock, E. et al. Multicolor spectral karyotyping of human chromosomes. Science 273, 494–497 (1996). · DOI · Paper page
  38. Nesbitt, M. N. & Francke, U. A system of nomenclature for band patterns of mouse chromosomes. Chromosoma 41, 145–158 (1973). · DOI · Paper page
  39. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  40. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011). · DOI · Paper page
  41. Brown, C. C. et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 179, 846–863 (2019). · DOI · Paper page

Cited by

See all 118

Metadata

Authors
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., Thorkelsson, A., Iacovelli, A. J., Kulaga, A., Fon, A., Michalowski, A. M., Hugo, W., Lo, R. S., Restifo, N. P., Sharan, S. K., Van Dyke, T., Goldszmid, R. S., Weaver Ohler, Z., Lee, M. P., Day, C.-P., & Merlino, G.
Venue
Nature Medicine
Published
2020-04-13
Volume
26
Issue
5
Pages
781-791
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3015906309
Cited by
118
References
37
FWCI
6.66
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. https://app.cochat.ai/papers/10.1038/s41591-020-0818-3
The paper
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., Thorkelsson, A., Iacovelli, A. J., Kulaga, A., Fon, A., Michalowski, A. M., Hugo, W., Lo, R. S., Restifo, N. P., Sharan, S. K., . . . Merlino, G. (2020). Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nature Medicine. https://doi.org/10.1038/s41591-020-0818-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.